What Has Been the Progress and Growth of the Cytokine Release Syndrome Treatment Market in Recent Years?
The cytokine release syndrome treatment market has seen considerable growth due to a variety of factors.
• The market for treatments of cytokine release syndrome has experienced substantial growth recently. The prediction for the market growth shows a jump from $1.25 billion in 2024 to $1.42 billion in 2025, representing a compound annual growth rate (CAGR) of 13.7%.
This growth during the historical phase can be linked to the escalating prevalence of cancer, a surge in the implementation of immunotherapy, an increase in biopharmaceutical investments, the rising number of clinical trials, and the expansion of personalized medicine.
What Is The Expected Growth In The Cytokine Release Syndrome Treatment Market Size Evolve over the Forecast Period?
The cytokine release syndrome treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for cytokine release syndrome treatment is projected to witness significant expansion in the upcoming years, reaching $2.35 billion by 2029 with a compound annual growth rate (CAGR) of 13.4%.
This anticipated growth in the forecast period is due to an increased frequency of autoimmune diseases, a rise in cancer therapy cases, the growing availability of targeted therapies, an escalation in biotechnology and life science investments, and the expanding use of monoclonal antibodies. The forecast period also reveals a few emerging trends including the application of biomarker-based therapies, the creation of next-generation IL-6 inhibitors, advancements in CAR-T cell therapy, the acceptance of biosimilars, and progression in monoclonal antibody therapies.
What Main Forces Are Fueling Expansion In The Cytokine Release Syndrome Treatment Market?
The surge in cancer treatments is anticipated to drive the cytokine release syndrome (CRS) treatment market's evolution. This rise in cancer treatments results from the escalating worldwide cancer occurrence and advances in diagnostic systems, fostering earlier identification and a broader variety of treatment solutions. Better survival rates, along with increased healthcare accessibility, augment the demand for these therapies. CRS treatment encompasses supportive care, anti-cytokine therapies, and continuous monitoring to handle symptoms and reduce the inflammatory reaction induced by cancer treatments. For example, the National Health Service (NHS), a UK-based healthcare organization, revealed in January 2023 that over 320,000 individuals underwent cancer treatment from November 2021 to October 2022, recording an all-time high and an increase of over 8,000. Thus, the growing frequency of cancer treatments is propelling the cytokine release syndrome treatment market.
What Are The Primary Segments In The Global Cytokine Release Syndrome Treatment Market?
The cytokine release syndrome treatment market covered in this report is segmented –
1) By Drug Type: Corticosteroids, Monoclonal Antibodies, Other Immunosuppressants
2) By Administration: Intravenous, Subcutaneous, Oral
3) By Application: Oncological Treatments, Autoimmune Disorders, Other Applications
4) By End User: Hospitals, Specialty Clinics, Home Care Settings
Subsegments:
1) Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) Monoclonal Antibodies: Tocilizumab (IL-6 Inhibitor), Siltuximab (IL-6 Inhibitor), Anakinra (IL-1 Receptor Antagonist)
3) Other Immunosuppressants: Janus Kinase (JAK) Inhibitors, Calcineurin Inhibitors, Tumor Necrosis Factor (TNF) Inhibitors
Pre-Book The Cytokine Release Syndrome Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Cytokine Release Syndrome Treatment Market?
Prominent firms in the cytokine release syndrome treatment industry are spearheading advancements in drug delivery technologies such as intravenous infusion in an effort to enhance treatment accuracy, minimize side effects, and improve patient results. The utilisation of intravenous infusion when combating cytokine release syndrome paves the way for rapid and precise drug administration into the bloodstream, ensuring immediate therapeutic effects. For instance, in September 2023, Chugai Pharmaceutical Co. Ltd, a pharmaceutical enterprise based in Japan, was given regulatory authorization from the Ministry of Health, Labor, and Welfare, also based in Japan, for Actemra (tocilizumab), a humanized anti-IL-6 receptor monoclonal antibody designed to treat cytokine release syndrome (CRS) triggered by different cancer treatments. Actemra Intravenous Infusion (offered in 80 mg, 200 mg, and 400 mg doses) presents an additional option for treating cytokine release syndrome (CRS) instigated by cancer therapy. This recent indication now permits Actemra's use as anti-cytokine therapy for CRS that arises from cancer treatments beyond tumor-specific T-cell infusion therapy.
Who Are the Key Players In The Cytokine Release Syndrome Treatment Market?
Major companies operating in the cytokine release syndrome treatment market are:
• Pfizer Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Chugai Pharmaceutical Co. Ltd.
• Incyte Corporation
• Swedish Orphan Biovitrum AB (publ)
• Bio-Techne Corporation
• GenScript Biotech Corporation
• Abcam plc
• Applied Biological Materials Inc.
• Poolbeg Pharma
• arigo Biolaboratories Corp.
• CytoAgents Inc
• bluebird bio Inc.
What Is The Most Dominant Region In The Cytokine Release Syndrome Treatment Market?
North America was the largest region in the cytokine release syndrome treatment market in 2024. The regions covered in the cytokine release syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
